Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions.

The reactivity in an avidin-biotin complex immunoperoxidase reaction with a large panel of anti-human melanoma associated antigen (MAA) and anti-HLA monoclonal antibodies of 24 primary and 11 metastatic acral lentiginous melanoma (ALM) lesions was compared to that of 12 primary and 12 metastatic nodular melanoma (NM) lesions. The expression of the membrane bound vitronectin receptor, Mr 110,000 MAA, Mr 97,000 MAA, and intercellular adhesion molecule-1 was significantly lower in both primary and metastatic ALM lesions than in their NM counterparts. Furthermore, primary ALM lesions displayed a significantly lower expression than primary NM lesions of the membrane bound high molecular weight melanoma associated antigen (HMW-MAA), Mr 110,000 MAA, Mr 100,000 MAA, 9-O-acetyl-GD3, GD2-GD3, and GD2, of the cytoplasmic monoclonal antibody 465.12 defined MAA and of transferrin receptor and of HLA-DQ and DP antigens; ALM metastases expressed a significantly lower level of carcinoembryonic antigen-MAA than NM metastases. These antigenic differences do not reflect an antigenic paucity of ALM cells, since ALM lesions express a higher level of T4-tyrosinase than NM lesions and a level of HLA Class I antigens similar to that of NM lesions. In view of the use of HMW-MAA, Mr 97,000 MAA, and GD3 in immunoscintigraphy and/or in immunotherapy, it is noteworthy that the three antigens are expressed in a similar high percentage of ALM metastases and of primary and metastatic NM lesions, while the HMW-MAA is expressed in a markedly lower percentage of primary ALM lesions than Mr 97,000 MAA and GD3. However, the degree of heterogeneity of HMW-MAA within a positive primary ALM lesion, as measured by the percentage of stained melanoma cells, is lower than that of Mr 97,000 MAA and GD3. The expression of the antigens investigated in ALM and NM lesions was not correlated with the presence of lymphocyte infiltrates, melanin content of melanoma cells, and epithelioid and spindle type of melanoma cells in the lesions. On the other hand, the survival of patients with ALM was inversely correlated with the expression of intercellular adhesion molecule 1 or HMW-MAA in their primary lesions. A potential role of HMW-MAA in the course of the disease is suggested by its significantly higher expression in metastatic than in primary ALM lesions.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  J. Johnson,et al.  Monoclonal antibody PAL-M1 recognizes the transferrin receptor and is a progression marker in melanocytic lesions. , 1990, The Journal of investigative dermatology.

[2]  S. Ferrone,et al.  Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. , 1990, Cancer research.

[3]  M. Herlyn,et al.  Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. , 1989, Cancer research.

[4]  J. Lehmann,et al.  MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Maio,et al.  Differential role of distinct determinants of intercellular adhesion molecule-1 in immunologic phenomena. , 1989, Journal of immunology.

[6]  S. Ferrone,et al.  Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. , 1989, Cancer research.

[7]  D. Ruiter,et al.  Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. , 1988, The Journal of investigative dermatology.

[8]  C. Perez-Mesa,et al.  Plantar lentiginous melanoma. A clinicopathologic study , 1987, Cancer.

[9]  L. Miller,et al.  Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. , 1987, Cancer research.

[10]  D. Elder,et al.  Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. , 1987, Cancer research.

[11]  M. Lark,et al.  The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface , 1986, The Journal of cell biology.

[12]  G. Mariani,et al.  Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. , 1986, Cancer research.

[13]  D. Elder,et al.  Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl-GD3. , 1985, The Journal of biological chemistry.

[14]  V. Hearing,et al.  Anti-T4-tyrosinase monoclonal antibodies--specific markers for pigmented melanocytes. , 1985, The Journal of investigative dermatology.

[15]  M. Melamed,et al.  Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. , 1985, Cancer research.

[16]  D. Ruiter,et al.  Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi. , 1985, The Journal of investigative dermatology.

[17]  N. Cheung,et al.  Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. , 1985, Cancer research.

[18]  M. Melamed,et al.  Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Reisfeld,et al.  Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. , 1984, The Journal of biological chemistry.

[20]  S. Larson,et al.  Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. , 1983, The Journal of clinical investigation.

[21]  J. Cairncross,et al.  Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets , 1982, The Journal of experimental medicine.

[22]  S. Ferrone,et al.  HETEROGENEOUS DISTRIBUTION OF THE DETERMINANTS DEFINED BY MONOCLONAL ANTIBODIES ON HLA‐A AND B ANTIGENS BEARING MOLECULES , 1982, Transplantation.

[23]  W. Coleman,et al.  Acral Lentiginous Melanoma: A Clinicopathologic Entity , 1982, Annals of surgery.

[24]  S. Ferrone,et al.  A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. , 1982, Journal of the National Cancer Institute.

[25]  S. Ferrone,et al.  Distribution and molecular characterization of a cell‐surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies , 1981, International journal of cancer.

[26]  L. Old,et al.  Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Brown,et al.  Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies. , 1980, The Journal of biological chemistry.

[28]  C. Schmoeckel Prognostic Index in Malignant Melanoma , 1980 .

[29]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[30]  K. Hellström,et al.  Human tumor antigens. , 1971, The New England journal of medicine.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[32]  J. Johnson,et al.  De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Ruiter,et al.  Immunodiagnostic and immunotherapeutic applications of anti human melanoma associated antigen monoclonal antibodies. , 1989, Carcinogenesis; a comprehensive survey.

[34]  M. Herlyn,et al.  Melanoma antigens: immunological and biological characterization and clinical significance. , 1988, Annual review of immunology.

[35]  J. Coligan,et al.  HLA‐DC antigens can serve as recognition elements for human cytotoxic T lymphocytes , 1984, European journal of immunology.

[36]  F. Bach,et al.  Detection of a novel human class II HLA antigen , 1983, Nature.